Phase Homogeneity in Ternary Amorphous Solid Dispersions and Its Impact on Solubility, Dissolution and Supersaturation - Influence of Processing and Hydroxypropyl Cellulose Grade

Overview

Journal Int J Pharm X

Specialty Pharmacology

Date 2024 Jan 1

PMID 38162398

Authors

Florian Postges

Jonas Lenhart

Edmont Stoyanov

Dominique J Lunter

Karl G Wagner

Affiliations

Soon will be listed here.

Abstract

As performance of ternary amorphous solid dispersions (ASDs) depends on the solid-state characteristics and polymer mixing, a comprehensive understanding of synergistic interactions between the polymers in regard of dissolution enhancement of poorly soluble drugs and subsequent supersaturation stabilization is necessary. By choosing hot-melt extrusion (HME) and vacuum compression molding (VCM) as preparation techniques, we manipulated the phase behavior of ternary efavirenz (EFV) ASDs, comprising of either hydroxypropyl cellulose (HPC)-SSL or HPC-UL in combination with Eudragit® L 100-55 (EL 100-55) (50:50 polymer ratio), leading to single-phased (HME) and heterogeneous ASDs (VCM). Due to higher kinetic solid-state solubility of EFV in HPC polymers compared to EL 100-55, we visualized higher drug distribution into HPC-rich phases of the phase-separated ternary VCM ASDs via confocal Raman microscopy. Additionally, we observed differences in the extent of phase-separation in dependence on the selected HPC grade. As HPC-UL exhibited decisive lower melt viscosity than HPC-SSL, formation of partially miscible phases between HPC-UL and EL 100-55 was facilitated. Consequently, as homogeneously mixed polymer phases were required for optimal extent of solubility improvement, the manufacturing-dependent differences in dissolution performances were smaller using HPC-UL, instead of HPC-SSL, i.e. using HPC-UL was less demanding on shear stress provided by the process.

References

Ohyagi N, Ueda K, Higashi K, Yamamoto K, Kawakami K, Moribe K . Synergetic Role of Hypromellose and Methacrylic Acid Copolymer in the Dissolution Improvement of Amorphous Solid Dispersions. J Pharm Sci. 2016; 106(4):1042-1050. DOI: 10.1016/j.xphs.2016.12.005. View

Wlodarski K, Zhang F, Liu T, Sawicki W, Kipping T . Synergistic Effect of Polyvinyl Alcohol and Copovidone in Itraconazole Amorphous Solid Dispersions. Pharm Res. 2018; 35(1):16. DOI: 10.1007/s11095-017-2313-1. View

Alzahrani A, Nyavanandi D, Mandati P, Youssef A, Narala S, Bandari S . A systematic and robust assessment of hot-melt extrusion-based amorphous solid dispersions: Theoretical prediction to practical implementation. Int J Pharm. 2022; 624:121951. DOI: 10.1016/j.ijpharm.2022.121951. View

Hanada M, Jermain S, Thompson S, Furuta H, Fukuda M, Williams 3rd R . Ternary Amorphous Solid Dispersions Containing a High-Viscosity Polymer and Mesoporous Silica Enhance Dissolution Performance†. Mol Pharm. 2020; 18(1):198-213. DOI: 10.1021/acs.molpharmaceut.0c00811. View

Hiew T, Zemlyanov D, Taylor L . Balancing Solid-State Stability and Dissolution Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and Drug-Polymer Interactions. Mol Pharm. 2021; 19(2):392-413. DOI: 10.1021/acs.molpharmaceut.1c00481. View

Thompson S, Davis Jr D, Miller D, Kucera S, Williams 3rd R . Pre-Processing a Polymer Blend into a Polymer Alloy by KinetiSol Enables Increased Ivacaftor Amorphous Solid Dispersion Drug Loading and Dissolution. Biomedicines. 2023; 11(5). PMC: 10215938. DOI: 10.3390/biomedicines11051281. View

Postges F, Kayser K, Appelhaus J, Monschke M, Gutschow M, Steinebach C . Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs. Pharmaceutics. 2023; 15(1). PMC: 9863516. DOI: 10.3390/pharmaceutics15010156. View

Thumma S, Majumdar S, ElSohly M, Gul W, Repka M . Preformulation studies of a prodrug of Delta9-tetrahydrocannabinol. AAPS PharmSciTech. 2008; 9(3):982-90. PMC: 2977038. DOI: 10.1208/s12249-008-9136-7. View

Hormann T, Jager N, Funke A, Murb R, Khinast J, Paudel A . Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization. Int J Pharm. 2018; 553(1-2):408-421. DOI: 10.1016/j.ijpharm.2018.10.035. View

10.

Yang Z, Nollenberger K, Albers J, Craig D, Qi S . Microstructure of an immiscible polymer blend and its stabilization effect on amorphous solid dispersions. Mol Pharm. 2013; 10(7):2767-80. DOI: 10.1021/mp400209w. View

11.

Six K, Verreck G, Peeters J, Brewster M, Van den Mooter G . Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci. 2003; 93(1):124-31. DOI: 10.1002/jps.10522. View

12.

Prasad D, Chauhan H, Atef E . Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects. J Pharm Sci. 2014; 103(11):3511-3523. DOI: 10.1002/jps.24137. View

13.

Sarpal K, Tower C, Munson E . Investigation into Intermolecular Interactions and Phase Behavior of Binary and Ternary Amorphous Solid Dispersions of Ketoconazole. Mol Pharm. 2019; 17(3):787-801. DOI: 10.1021/acs.molpharmaceut.9b00970. View

14.

Monschke M, Wagner K . Impact of HPMCAS on the Dissolution Performance of Polyvinyl Alcohol Celecoxib Amorphous Solid Dispersions. Pharmaceutics. 2020; 12(6). PMC: 7356348. DOI: 10.3390/pharmaceutics12060541. View

15.

Chiou W, RIEGELMAN S . Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971; 60(9):1281-302. DOI: 10.1002/jps.2600600902. View

16.

Brouwers J, Brewster M, Augustijns P . Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?. J Pharm Sci. 2009; 98(8):2549-72. DOI: 10.1002/jps.21650. View

17.

Lyu S, Sparer R, Hobot C, Dang K . Adjusting drug diffusivity using miscible polymer blends. J Control Release. 2005; 102(3):679-87. DOI: 10.1016/j.jconrel.2004.11.007. View

18.

Meng F, Gala U, Chauhan H . Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques. Drug Dev Ind Pharm. 2015; 41(9):1401-15. DOI: 10.3109/03639045.2015.1018274. View

19.

Higashi K, Hayashi H, Yamamoto K, Moribe K . The effect of drug and EUDRAGIT® S 100 miscibility in solid dispersions on the drug and polymer dissolution rate. Int J Pharm. 2015; 494(1):9-16. DOI: 10.1016/j.ijpharm.2015.08.007. View

20.

Que C, Lou X, Zemlyanov D, Mo H, Indulkar A, Gao Y . Insights into the Dissolution Behavior of Ledipasvir-Copovidone Amorphous Solid Dispersions: Role of Drug Loading and Intermolecular Interactions. Mol Pharm. 2019; 16(12):5054-5067. DOI: 10.1021/acs.molpharmaceut.9b01025. View